Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide informed consent
Histologically confirmed adenocarcinoma of the prostate
History of radical therapy (i.e., radical prostatectomy, radiotherapy, brachytherapy or prostatectomy with salvage radiotherapy)
Serum testosterone levels 8.0 nmol/L (230 ng/dL) or greater
Not currently undergoing treatment for hyperlipidemia or diabetes mellitus
LDL-cholesterol levels 5 mmol/L or lower
HgA1c 6.5% or lower
PSA levels between 2 and 5 ng/mL
You may not be if
Subjects that have been treated for prostate cancer with any of the following:
i. Cytotoxic chemotherapy; ii. Hormonal therapy within past 3 years; iii. Oral glucocorticoids; iv. Gonadotropin-releasing hormone (GnRH) analogues (e.g., leuprolide, goserelin, degarelix)
Past treatment with the 5-α reductase inhibitors finasteride and dutasteride within past 5 years
Past treatment with drugs with antiandrogenic properties (e.g., flutamide, bicalutamide, ketoconazole, progestational agents) within 6 months prior to screening
Use of metformin or statins within past 2 years
Planned or concurrent use of metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Known hypersensitivity or intolerance to metformin or atorvastatin
Any clinically significant laboratory abnormalities (e.g., severe renal or hepatic impairment) which in the judgment of the investigator would affect the patient's health or the outcome of the trial
Any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as New York Heart Association (NYHA) class III or IV, history of any type of acidosis, habitual intake of 4 or more alcoholic beverages per day)
Abnormal liver function test
Abnormal organ and marrow function
Clareo Health | LIpitor and biGuanide to Androgen Delay Trial
